+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Liposomal N,N,N-trimethylsphingosine (TMS) as an inhibitor of B16 melanoma cell growth and metastasis with reduced toxicity and enhanced drug efficacy compared to free TMS: cell membrane signaling as a target in cancer therapy III



Liposomal N,N,N-trimethylsphingosine (TMS) as an inhibitor of B16 melanoma cell growth and metastasis with reduced toxicity and enhanced drug efficacy compared to free TMS: cell membrane signaling as a target in cancer therapy III



Cancer Research 54(8): 2213-2217



We demonstrated previously that N,N,N-trimethylsphingosine (TMS) and N,N-dimethylsphingosine (DMS), but not unsubstituted sphingosine, produce significant inhibitory effects on in vivo growth of human tumor cells in nude mice (K. Endo et al., Cancer Res., 51: 1613-1618, 1991) and on metastasis of B16 melanoma cells in syngeneic mice (H. Okoshi et al., Cancer Res., 51: 6019-6024, 1991).

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 008961373

Download citation: RISBibTeXText

PMID: 8174128


Related references

Cooperative inhibitory effect of N,N,N-trimethylsphingosine and sphingosine-1-phosphate, co-incorporated in liposomes, on B16 melanoma cell metastasis: Cell membrane signaling as a target in cancer therapy IV. International Journal of Oncology 7(3): 487-494, 1995

Cell membrane signaling as target in cancer therapy ii. inhibitory effect of n n n trimethylsphingosine on metastatic potential of murine b16 melanoma cell line through blocking of tumor cell dependent platelet aggregation. Cancer Research 51(22): 6019-6024, 1991

Cell membrane signaling as target in cancer therapy: inhibitory effect of N,N-dimethyl and N,N,N-trimethyl sphingosine derivatives on in vitro and in vivo growth of human tumor cells in nude mice. Cancer Research 51(6): 1613-1618, 1991

Novel C-Terminal Hsp9 Inhibitor for Head and Neck Squamous Cell Cancer HNSCC with in vivo Efficacy and Improved Toxicity Profiles Compared with Standard Agents. Annals of Surgical Oncology 19(3 Suppl.): 483-490, 2012

Novel C-terminal Hsp90 inhibitor for head and neck squamous cell cancer (HNSCC) with in vivo efficacy and improved toxicity profiles compared with standard agents. Annals of Surgical Oncology 19(Suppl. 3): S483-S490, 2012

Exth-03. Enhanced In Vivo Efficacy And Safety Of Combination Temozolomide And Bromodomain Inhibitor Therapy For Gliomas Using ATargeted Dual Drug-Loading Stealth Liposomal Carrier. Neuro-Oncology 19(Suppl_6): vi73, 2017

Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine. Molecular Oncology 13(7): 1503-1518, 2019

Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis. Oncotarget 7(3): 3635-3644, 2016

Significance of PI3K/AKT signaling pathway in metastasis of esophageal squamous cell carcinoma and its potential as a target for anti-metastasis therapy. Oncotarget 8(24): 38755-38766, 2017

Direct Melanoma Cell Contact Induces Stromal Cell Autocrine Prostaglandin E2-EP4 Receptor Signaling That Drives Tumor Growth, Angiogenesis, and Metastasis. Journal of Biological Chemistry 290(50): 29781-29793, 2015

MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells. Oncotarget 7(47): 77378-77388, 2016

Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood 111(6): 3116-3125, 2008

Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity. Journal of Medicinal Chemistry 45(21): 4706-4715, 2002

Comparative efficacy of vascular endothelial growth factor VEGF tyrosine kinase inhibitor TKI and mammalian target of rapamycin mTOR inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VE. 2012

Phospholipase D in cell signaling: from a myriad of cell functions to cancer growth and metastasis. Journal of Biological Chemistry 289(33): 22557-22566, 2014